Sensitivity Analysis | No. of trials | rs | 95%CI |
---|---|---|---|
ΔORR ~ HR of OS | |||
 Line of therapy | |||
  First-line | 39 | 0.685 | 0.471, 0.822 |
   ≥ 2nd-line | 64 | 0.342 | 0.103, 0.544 |
 Phase of trial | |||
  Phase II | 60 | 0.399 | 0.163, 0.591 |
  Phase III | 52 | 0.511 | 0.277, 0.688 |
 Masking | |||
  Double-blind | 35 | 0.259 | −0.081, 0.545 |
  Open-label | 76 | 0.536 | 0.354, 0.680 |
Overall | 112 | 0.462 | 0.303, 0.597 |
ΔORR ~ HR of PFS | |||
 Line of therapy | |||
  First-line | 36 | 0.767 | 0.587, 0.875 |
   ≥ 2nd-line | 68 | 0.787 | 0.675, 0.863 |
 Phase of trial | |||
  Phase II | 60 | 0.792 | 0.674, 0.870 |
  Phase III | 54 | 0.673 | 0.495, 0.797 |
 Masking | |||
  Double-blind | 36 | 0.703 | 0.487, 0.838 |
  Open-label | 77 | 0.789 | 0.672, 0.852 |
Overall | 114 | 0.764 | 0.686, 0.861 |
HR of PFS ~ HR of OS | |||
 Line of therapy | |||
  First-line | 48 | 0.768 | 0.621, 0.863 |
   ≥ 2nd-line | 81 | 0.550 | 0.377, 0.686 |
 Phase of trial | |||
  Phase II | 62 | 0.475 | 0.258, 0.647 |
  Phase III | 72 | 0.650 | 0.492, 0.766 |
 Masking | |||
  Double-blind | 42 | 0.676 | 0.469, 0.813 |
  Open-label | 95 | 0.570 | 0.417, 0.692 |
Overall | 138 | 0.584 | 0.462, 0.684 |